NICE technology appraisal guidance
Issued: July 2012
TA261

Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism

This is an extract from the guidance. The complete guidance is available at guidance.nice.org.uk/ta261

1 Guidance

1.1 Rivaroxaban is recommended as an option for treating deep vein thrombosis and preventing recurrent deep vein thrombosis and pulmonary embolism after a diagnosis of acute deep vein thrombosis in adults.